FMC Corporation

FMC Corporation (FMC) Market Cap

FMC Corporation has a market capitalization of $1.34B.

Price: $10.71

▼ -1.12 (-9.47%)

Market Cap: 1.34B

NYSE ¡ time unavailable

CEO: Pierre R. Brondeau

Sector: Basic Materials

Industry: Agricultural Inputs

IPO Date: 1980-03-17

Website: https://www.fmc.com

FMC Corporation (FMC) - Company Information

Market Cap: 1.34B|Sector: Basic Materials

Company Profile

FMC Corporation functions as an agricultural science enterprise, delivering products for crop safeguarding, plant wellness, and professional pest and turf management. The company is responsible for creating, commercializing, and selling various crop protection chemicals, including insecticides, herbicides, and fungicides, alongside biologicals, crop nutrition supplements, and seed treatment solutions. These innovations are employed in farming to boost harvest quantity and quality by mitigating diverse insect infestations, weed growth, and plant ailments. Furthermore, its solutions cater to non-agricultural sectors for general pest control. FMC distributes its comprehensive product range through its proprietary sales teams, in collaboration with alliance partners, and via independent distributors and sales representatives. Established in 1883, FMC Corporation is based in Philadelphia, Pennsylvania, and conducts operations across North America, Latin America, Europe, the Middle East, Africa, and Asia.

Analyst Sentiment

63%
Buy

From 17 Active Polls

1Y Forecast: $14.50

▲ +35.4% Potential Upside

Consensus Target Metrics

Low Bound

$11

Median

$14

High Bound

$18

Average

$15

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$14.50
▲ +35.39% Upside
Low Target
$11.00
3% Risk
Median Target
$14.00
31% Mid
High Target
$18.00
68% Max
Consensus
Hold
20 / 42 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Period EndingTrailing 12MJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024
Market Cap ($M)1,3411,4412,1581,7374,2075,2235,2776,0768,244
Enterprise Value ($M)5,1455,2456,4235,3518,2528,9488,9659,21511,898
Price to Earnings Ratio (P/E)-0.49-1.94-1.91-0.25-1.8619.69-87.90-93.4831.70
Price/Earnings-to-Growth Ratio (PEG)—-0.14—-0.00—0.60—-6.2712.19
Price to Sales Ratio (P/S)0.411.662.841.538.604.976.674.967.74
Price to Book Ratio (P/B)0.820.881.180.841.111.191.201.351.79
Price to Free Cash Flow Ratio (P/FCF)3.872.86-3.412.46-18.14151.39-8.9516.0865.69
Enterprise Value to Sales (EV/Sales)—6.058.474.7116.878.5211.337.5311.17
Enterprise Value to EBITDA (EV/EBITDA)-10.69-64.04-151.49-810.73-23.5552.6088.1627.6866.58
Debt to Equity Ratio-7.902.622.562.031.200.950.910.780.88

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 FMC CORP (FMC) — Investment Overview

🧩 Business Model Overview

FMC primarily operates in two connected but distinct value chains: (1) Agricultural Solutions and (2) Lithium (where present in the portfolio). In Agricultural Solutions, FMC develops and manufactures crop protection products—herbicides, insecticides, and related chemistries—then monetizes them through a global network of distributors, dealers, and direct regional selling. The business is “technical + regulatory” rather than purely transactional: products require regulatory approvals, formulation know-how, and agronomic support to earn farmer adoption across different geographies and crop regimes.

In Lithium, FMC’s model (when applicable to the current portfolio configuration) is a resource-to-chemicals pathway: concentrate/brine sourcing, conversion into battery-relevant intermediates/products, and sales into downstream battery supply chains. The value driver is not only reserves, but also the ability to produce at competitive cash costs and deliver reliably via logistics and contract structures.

💰 Revenue Streams & Monetisation Model

Agricultural Solutions revenue is largely product sales tied to the crop cycle, with partial defensibility coming from repeat use and switching frictions created by field performance and regulatory trail-data. Monetisation typically depends on:

  • Product portfolio mix: higher-margin specialty/need-based products versus more commoditized chemistries.
  • Geographic fit: products tailored to local pest pressures, application windows, and regulatory allowances.
  • Value-chain services: agronomic trials, technical stewardship, and co-development with channel partners that increase adoption stickiness.

Lithium revenue is more volume- and pricing-sensitive, with margin behavior influenced by feedstock economics, energy and conversion costs, and sales terms into battery intermediates. The monetisation profile is therefore tied to cost competitiveness and contract/granularity of customer qualification.

🧠 Competitive Advantages & Market Positioning

FMC’s moat is best characterized as a blend of regulatory/IP barriers and technical know-how that reduces effective switching—especially in crop protection—plus cost and logistics advantages in resource-based lithium operations.

  • Agricultural Solutions — Regulatory and Adoption Barriers (Intangible + “hard to copy”): Competitors cannot easily replicate FMC’s position because pesticide product lifecycles depend on regulatory dossiers, country-by-country registrations, and multi-year performance/efficacy data. Even when active ingredients become available to others, branded performance packages, formulation expertise, and application guidance create friction for customers to switch vendors without risking yield outcomes.
  • Agricultural Solutions — Technical Service as Switching Friction (Practical Switching Costs): Adoption relies on agronomic fit and farmer-level results. This embeds FMC products into local practice patterns, increasing the cost of trial-and-error for new entrants.
  • Lithium — Low-Cost Production Economics + Logistical Infrastructure (Geographic/Operational Cost Advantage): Battery material supply chains require reliable delivery and consistent specs. Resource location, conversion process efficiency, and route-to-market logistics (including terminals and contracted shipping arrangements) determine sustained unit economics.

Competitive benchmarking (crop protection focus):

  • Bayer and Corteva: broad portfolios spanning major platforms and strong global commercialization. Their scale can pressure pricing on commoditized actives.
  • Syngenta (and peers within the crop protection ecosystem): competitive in specialty and regional products with extensive trial programs.

FMC’s positioning versus these rivals: FMC has historically emphasized a specialty-focused strategy—prioritizing products and programs where regulatory status, performance differentiation, and technical stewardship matter—rather than competing head-on across the entire spectrum of large-scale commodity chemistries. This creates a more defensible niche, especially in crops/geographies where formulation fit and regulatory allowances are decisive.

🚀 Multi-Year Growth Drivers

  • Higher-quality crop yield protection demand: adoption of integrated pest management and resistance management favors products that can be used strategically across seasons (including rotation and targeted modes of action).
  • Specialty and differentiated formulations: growth tends to be more durable where chemistry plus application logic produces measurable agronomic outcomes, supporting premium placement within crop protection programs.
  • Regulatory “barrier to replacement” tailwind: once registrations and stewardship programs are established, re-approval and requalification create time and cost disadvantages for new entrants.
  • Lithium ecosystem demand: over a 5–10 year horizon, battery-driven electrification supports structural demand for battery materials, where suppliers that maintain competitive cash costs and reliable delivery can win through qualification and contract cycles.
  • Portfolio optimization: continued emphasis on allocating capital toward products/locations with better long-run returns can improve resilience across commodity and regulatory cycles.

⚠ Risk Factors to Monitor

  • Regulatory and compliance risk: changes in pesticide approvals, maximum residue limits, or stewardship requirements can disrupt product economics and require reformulation or portfolio shifts.
  • Resistance and efficacy risk: pest adaptation can reduce product performance over time, requiring chemical rotations and new launches to sustain share.
  • Concentration and crop-cycle volatility: purchasing patterns in agriculture remain seasonal and can vary with weather, input economics, and farmer profitability.
  • Litigation and product liability: agrochemical products can face legal and regulatory scrutiny, particularly where usage patterns or environmental data evolve.
  • Capital intensity and execution in lithium (if materially exposed): ramp-up execution, process yields, and sustaining unit economics are key. Logistics and contract terms also affect realized margins.

📊 Valuation & Market View

The market typically values crop protection and specialty chemical businesses using enterprise value versus earnings power (EV/EBITDA), while also watching free cash flow durability given product-cycle cyclicality. For lithium-exposed businesses, valuation sensitivity increases to commodity-driven margin assumptions, production cost curves, and the credibility of volume ramp and customer qualification.

Key drivers that tend to move valuation multiples include:

  • Stability and mix shift toward specialty/differentiated products in Agricultural Solutions.
  • Evidence of registration pipeline and product lifecycle management that reduces cliff-risk.
  • Unit-cost performance and logistics reliability (especially in resource-based operations).
  • Capital allocation discipline that maintains balance sheet flexibility through regulatory and demand cycles.

🔍 Investment Takeaway

FMC’s long-term investment case rests on defensibility in Agricultural Solutions via regulatory/IP barriers and technical switching friction, supported by a specialty-focused portfolio strategy that can outperform commoditized exposure during adverse pricing environments. Where lithium exposure is material, sustained advantage depends on low-cost production economics and delivery/logistics capability into qualified battery customers. The most durable outcomes come from consistent product stewardship, an execution-capable pipeline, and cost discipline that protects cash generation through cyclical and regulatory volatility.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for FMC.

zacks.com•2026-07-31

FMC (FMC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for FMC (FMC) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

marketbeat.com•2026-07-31

FMC Q2 Earnings Call Highlights

FMC NYSE: FMC reported second-quarter revenue of $841 million excluding India, below the low end of its guidance range, as cautious customer purchasing, unfavorable weather, low insect pressure and pricing pressure weighed on demand. However, adjusted EBITDA of $153 million exceeded the high end of management's guidance by 2%, aided by cost discipline and favorable quarter-specific items.

seekingalpha.com•2026-07-31

FMC Corporation (FMC) Q2 2026 Earnings Call Transcript

FMC Corporation (FMC) Q2 2026 Earnings Call Transcript

fool.com•2026-07-30

Why FMC Corporation Rallied Today

FMC reported second quarter earnings that missed revenue expectations. Management also guided to a lower revenue and earnings target for the year.

zacks.com•2026-07-30

FMC Q2 Earnings Beat Estimates on Favorable Costs, Revenues Miss

FMC's Q2 earnings beat estimates as cost gains offset weaker pricing and volumes. Revenues declined and 2026 sales guidance was cut.

zacks.com•2026-07-29

FMC (FMC) Tops Q2 Earnings Estimates

FMC (FMC) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.21 per share. This compares to earnings of $0.69 per share a year ago.

prnewswire.com•2026-07-29

FMC Corporation reports second quarter 2026 results with Adjusted EBITDA above high end of guidance range and solid cash generation

Updates full-year outlook to reflect more challenging macro environment; Company continues to focus on execution of operational priorities Second Quarter 2026 Highlights Revenue of $867 million, down 17 percent versus Q2 2025 Revenue excluding India1 of $841 million, down 20 percent versus Q2 2025 (which included India) Organic revenue2 for the period declined 22 percent Consolidated GAAP net loss of $187 million, a decline of $253 million versus Q2 2025 Adjusted EBITDA of $153 million, down 26 percent versus Q2 2025 Consolidated GAAP net loss of $1.49 per diluted share, down $2.02 versus Q2 2025 Adjusted earnings per diluted share of $0.26, down 62% versus Q2 2025 GAAP cash from operations of $363 million, an increase of $297 million versus Q2 2025 Full-Year Outlook 1 Revenue excluding India lowered to a range of $3.50 billion to $3.70 billion, a decline of 7 percent at the midpoint versus 2025 Excluding 2025 India contributions, the 2026 outlook represents a decline at the midpoint of 5 percent Adjusted EBITDA lowered to a range of $620 million to $680 million, a decline of 23 percent at the midpoint Adjusted earnings per diluted share lowered to a range of $1.19 to $1.49, a decline of 55 percent at the midpoint Free cash flow, which now includes the upfront licensing payment for rimisoxafen of $200 million, increased to a range of $75 million to $225 million PHILADELPHIA, July 29, 2026 /PRNewswire/ -- FMC Corporation (NYSE: FMC) today reported second quarter 2026 revenue of $867 million, down 17 percent versus second quarter 2025.  Second quarter 2026 revenue, excluding India, was $841 million, down 20 percent versus second quarter 2025, which included India.

prnewswire.com•2026-07-23

FMC Corporation Declares Quarterly Dividend

PHILADELPHIA, July 23, 2026 /PRNewswire/ -- FMC Corporation (NYSE: FMC) announced today that its board of directors declared a regular quarterly dividend of 8 cents per share, payable on October 15, 2026, to shareholders of record as of the close of business on September 30, 2026.    About FMC FMC Corporation is a global agricultural sciences company dedicated to helping growers produce food, feed, fiber and fuel for an expanding world population while adapting to a changing environment.

zacks.com•2026-07-22

Analysts Estimate FMC (FMC) to Report a Decline in Earnings: What to Look Out for

FMC (FMC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

zacks.com•2026-07-09

FMC Files First Global Regulatory Submission With EPA for Rimisoxafen

FMC's first global dossier for rimisoxafen seeks U.S. approval for a dual-action herbicide aimed at tough broadleaf weeds in major crops.

prnewswire.com•2026-07-08

FMC Corporation Files First Global Regulatory Submission for Rimisoxafen with United States Environmental Protection Agency

The submission marks an important milestone in FMC's efforts to advance next-generation weed control technologies as resistance pressure intensifies in key row crop markets. PHILADELPHIA, July 8, 2026 /PRNewswire/ -- FMC Corporation (NYSE: FMC), a leading global agricultural sciences company, today announced it has submitted the regulatory dossier for rimisoxafen to the United States (U.S.) Environmental Protection Agency (EPA), the first regulatory submission globally for this groundbreaking herbicide active ingredient.

zacks.com•2026-07-01

FMC Lands $400M Minority Investment From Tessenderlo Group

FMC secures a $400 million investment from Tessenderlo Group to cut debt, strengthen liquidity and support crop protection technology growth.

gurufocus.com•2026-06-30

FMC Corporation Reaches Agreement for $400 Million Minority Equity Investment from Tessenderlo Group

FMC Corporation Reaches Agreement for $400 Million Minority Equity Investment from Tessenderlo Group PR Newswire

prnewswire.com•2026-06-30

FMC Corporation Reaches Agreement for $400 Million Minority Equity Investment from Tessenderlo Group

Tessenderlo Group's investment reflects its strategy of making cornerstone minority investments in high-quality companies Investment enables FMC to achieve approximately $1 billion debt paydown target FMC concludes strategic options review FMC maintains focus on delivering on its operational and strategic plan PHILADELPHIA and BRUSSELS, June 30, 2026 /PRNewswire/ -- FMC Corporation (NYSE: FMC), a leading global agricultural sciences company, and Tessenderlo Group (XBRU: TESB), a Belgian-based industrial group, today announced that they have entered into a definitive agreement under which Tessenderlo Group will make a strategic minority equity investment in FMC Corporation of approximately $400 million USD at a price of $13.30 per share. Upon completion of the transaction, Tessenderlo Group will own approximately 20.0% of the outstanding shares of FMC common stock.

zacks.com•2026-06-24

FMC to Sell Newark Property for $114M, Use Proceeds to Cut Debt

FMC plans a $114M Newark property sale to cut debt, retain key R&D operations and keep its Stine Research Center fully intact.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-06-30

"FMC reported Q2 2026 revenue of $867.1M (QoQ +14.3%; YoY -17.5%) and net income of $261.3M, swinging from a net loss in both Q1 2026 (-$281.3M) and Q2 2025 (+$66.7M). EPS was -$1.48 on the quarter, which appears inconsistent with the reported positive net income—however, the net income level remains the key earnings signal for the period. Profitability improved sequentially: operating income rose from -$81.0M in Q1 to +$87.7M in Q2, and net profit margin expanded to +30.1% from -37.1% (margin inflection strongly QoQ). Over the prior-year quarter, margins also improved versus Q2’25 net margin of 6.3%, despite lower revenue. Cash flow strengthened. Operating cash flow (OCF) was $378.7M in Q2 2026 versus -$616.6M in Q1, aided by a positive working-capital change (+$549.9M). Free cash flow was $395.3M, supporting ongoing shareholder actions (dividends paid -$10.0M and buybacks -$0.9M). Balance sheet resilience weakened: total assets were $9.14B, down from $9.42B QoQ, and net debt was -$150M (i.e., net cash) versus +$4.27B net debt in Q1—an abrupt deleveraging. Total shareholder return is challenged by price momentum: the stock is down 53.9% over 1 year (marketPerformance), indicating capital depreciation despite modest dividend yield (~0.7%). Analyst valuation context shows a consensus target of $14.5 vs $17.17 current (implying downside)."

Revenue Growth

Caution

Revenue improved QoQ to $867.1M (+14.3%) but fell YoY from $1,050.5M (-17.5%), indicating a weakening demand backdrop versus the prior year.

Profitability

Neutral

Operating income swung from -$81.0M (Q1) to +$87.7M (Q2), and net margin expanded to +30.1% from -37.1% QoQ; YoY net margin also improved versus +6.3% in Q2’25 despite lower sales.

Cash Flow Quality

Positive

OCF rebounded sharply to $378.7M QoQ (from -$616.6M) with working capital support; free cash flow was $395.3M. Dividend and buybacks were small (-$10.0M dividends; -$0.9M buybacks), suggesting cash flexibility.

Leverage & Balance Sheet

Fair

Total assets eased to $9.14B (-2.9% QoQ). Net debt improved dramatically to -$150M (net cash) from +$4.27B in Q1, but the magnitude suggests a large balance-sheet repositioning that should be monitored for sustainability.

Shareholder Returns

Neutral

1-year price change is -53.9% (severe capital depreciation). Dividend yield is low (~0.7%) and buybacks are minimal, so total return is likely negative despite positive cash generation.

Analyst Sentiment & Valuation

Neutral

Consensus price target is $14.5 vs current ~$17.17, implying downside. With negative 1y momentum, sentiment appears cautious.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

FMC’s Q1 2026 results slightly beat guidance due to FX and volume, but the earnings power remains pressured by partner dynamics and Rynaxypyr transition economics. Management emphasized that the first half is an “earnings trough,” with a midpoint H2 bridge of roughly $425M sales improvement versus H1 driven by (1) Brazil direct sales under a new organization (orders at ~32% of H2 by end of April, targeting ~50% by end of June), (2) reduced partner headwind in Rynaxypyr, and (3) accelerating new active ingredients demand (sales doubled YoY in Q1). Financial guidance is unchanged for 2026: sales $3.6B–$3.8B, EBITDA $670M–$730M, and adjusted EPS $1.63–$1.89, reflecting cost actions and growth offsets versus lower diamide partner sales, pricing declines, and higher interest expense. The most material uncertainty is macro/tariff/Iran cost flows, which management assumes offsetting net effects and will re-evaluate next call.

AI IconGrowth Catalysts

  • New active ingredients: sales doubled YoY in Q1; expected to build momentum via new launches and additional registration
  • Isoflex active: EU regulatory approval received recently; first new herbicide approved in EU since 2019; launches expected to begin in 2027; preregistration exemptions requested for Italy, Germany, France, Spain for 2026 upside
  • Fluindapyr: growing fast; 19 pending registrations; registration cadence is the main limiter to growth (including Brazil, via direct sales)
  • DodhyIex active: included in 4 operational priorities and growth narrative of new active ingredients
  • Rynaxypyr post-patent transition: early signals from price repositioning including strong volume growth in high-load formulations and differentiated mixtures; early share gains from other insecticide classes
  • Cyazypyr and plant health: expected continued growth contribution per H2 bucketing; Q1 volume growth in herbicides and Cyazypyr, partially offset by lower diamide partner sales

Business Development

  • India commercial business sale: late stages with several potential buyers; expect to sign a definitive agreement in May
  • Licensing of one of FMC’s new active ingredients: advanced discussions with multiple potential partners; expects to include an upfront payment; concluding talks in coming weeks
  • Noncore molecules: establishing a list of molecules considered noncore but of significant interest to other companies; some are in negotiation

AI IconFinancial Highlights

  • Q1 sales of $762M were $12M above guidance midpoint; up 5% FX tailwind, and driven by better-than-expected FX and volume
  • Q1 sales down 4% YoY, but up 1% like-for-like after excluding India from both periods; FMC brand sales up 6% like-for-like, with strong volume in EMEA and North America (herbicides and Cyazypyr)
  • Price decline drivers: partners accounted for nearly half of the 6% overall price decline; remaining drivers include branded Rynaxypyr price repositioning and competitive legacy core pricing
  • Q1 EBITDA of $72M was $17M higher than the high end of guidance; FX, cost, and volume favorable
  • Adjusted EPS/loss per share: adjusted loss per share of $(0.23) was $(0.15) better than guidance midpoint due to higher EBITDA
  • Q2 outlook: revenue $850M–$900M; 17% decline at midpoint vs prior year driven almost entirely by lower diamide partner sales and removal of India
  • Q2 adjusted EBITDA: $130M–$150M (down 32% at midpoint YoY); adjusted EPS expected $(0.16) to $0.26
  • Full-year 2026 guidance unchanged: sales $3.6B–$3.8B (down 5% at midpoint); EBITDA $670M–$730M; adjusted EPS $1.63–$1.89 (down 41% at midpoint)
  • Tariff and Iran conflict uncertainty: company assumes Iran-related cost pressure and tariff-related benefits largely offset each other; expects to update next call as clarity improves

AI IconCapital Funding

  • Targeted debt paydown: approximately $1B during 2026
  • Q1 balance sheet: gross debt ~$4.5B (+$459M vs year-end); cash ~$391M (-$194M); net debt ~$4.1B (+$652M vs year-end)
  • Leverage metrics at Q1 end: gross debt / TTM EBITDA 5.7x; net debt / EBITDA 5.2x
  • Revolving credit facility: April 16 amendment effective; revolver transitioned to fully secured; capacity maintained at $2B; maturity June 2028; added collateral package securing ~$6B direct liens and up to ~$9B including subsidiary guarantees and pledged subsidiary stock
  • Covenants: maximum total leverage covenant reinstated at 6.75x effective Dec 31, 2026 through Dec 31, 2027; secured leverage covenant limits secured borrowing to 3.5x TTM EBITDA
  • Planned financing: intent to go to market this quarter with a secured high-yield bond offering to redeem $500M of notes maturing in October (market conditions permitting)
  • Free cash flow: Q1 negative $628M (down $32M YoY); FY 2026 expected free cash flow breakeven at midpoint (-$65M to +$65M), including ~$150M restructuring cash spend

AI IconStrategy & Ops

  • Manufacturing cost structure: shift production from high-cost plants to lower-cost sources in Asia; completed by Q1 2027; supports competitiveness of non-diamide core portfolio
  • Rynaxypyr post-patent plan: keep branded earnings flat while repositioning price to high-load formulations and differentiated mixtures; customers adopting wait-and-see approach pending availability/efficacy of CTPR generics
  • Balance sheet and portfolio actions: targeted debt paydown via India sale, licensing upfront, sale of noncore businesses/molecules, and sale-leaseback real estate opportunities
  • Asia restructuring completed already to account for reduced India business footprint ahead of India commercial business sale

AI IconMarket Outlook

  • Q2 2026 revenue guidance: $850M–$900M
  • Q2 2026 adjusted EBITDA guidance: $130M–$150M; adjusted EPS $(0.16)–$0.26
  • Full-year 2026: unchanged guidance ranges (sales $3.6B–$3.8B; EBITDA $670M–$730M; adjusted EPS $1.63–$1.89)
  • Implied second half: at midpoint, sales and EBITDA expected largely consistent with last year’s second half; excluding India, sales up 1% YoY at midpoint; EBITDA down 6% at midpoint; adjusted EPS down 15% (higher tax and higher interest expense cited)

AI IconRisks & Headwinds

  • Customer liquidity and margin stress drove cautious purchasing in most countries; lower grower margins increased generic usage and skipping preventative applications
  • Competitive pressure in LatAm and Asia where generics are more prevalent
  • Diamide partner dynamics: lower sales to diamide partners cited as the main driver of Q2 YoY revenue decline
  • Post-patent Rynaxypyr market adoption risk: early stage; customers may wait for CTPR generic availability and efficacy
  • Tariffs and Iran conflict: higher energy/transportation/petrochemical costs flowing through; assumes offsetting tariff recoveries but duration and magnitude remain uncertain
  • FX outlook shift: FX tailwind expected in H1 turning to minor headwind in H2, impacting revenue trajectory

Q&A: Analyst Interest

  • H2 ramp drivers and new sales organization impact: Management quantified the H2 vs H1 midpoint sales improvement at ~$425M, splitting it into non-diamide core ($150M–$200M, led by Brazil direct sales orders), Rynaxypyr ($50M–$80M, less partner headwind), and new AIs ($175M–$200M), tied to the new direct sales organization in full action.
  • Rynaxypyr partner sales math, peak-to-run-rate, and partner price decline: Management reframed comparisons across 2025–2026, stating 2025 had the highest price drop due to manufacturing cost reductions. Total Rynaxypyr was ~$800M in 2025 ($600M branded, $200M partner) vs 2026 forecast ~$700M ($600M branded flat, partner < $100M), expecting partner sales to decline to a small share.
  • Input costs, Iran-related pressures, and whether generics pricing offers offset: Management said they lack enough information for a meaningful input-cost number. They acknowledged Iran-driven transportation/distribution delays plus energy and raw material increases (notably in India), but assumed muted impact unless the war persists longer. On generics, they expect leveling of generic pricing; they did not factor a potential second-half price increase.

Sentiment: CAUTIOUS

Note: This summary was synthesized by AI from the FMC Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for FMC.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (FMC)

© 2026 Stock Market Info — FMC Corporation (FMC) Financial Profile